Pyxis Oncology, Inc.

PYXS · Nasdaq · SIC 2834: Pharmaceutical Preparations
81
SEC Filings

Business Summary

. Overview Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Our lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational novel antibody-drug conjugate (ADC) that uniquely targets the splice variant of fibronectin, extradomain-B of fibronectin (EDB+FN), a non-cellular structural c...

Next Earnings

Q2 FY2026 — expected 2026-08-08

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionPYXSdiscussed_in_filing Cybersecurity
topic_mentionPYXSdiscussed_in_filing Cybersecurity
topic_mentionPYXSdiscussed_in_filing Healthcare & Bio
topic_mentionPYXSdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-232025-12-310001193125-26-118532EDGAR96K words
2025-03-182024-12-310000950170-25-040771EDGAR—
2024-03-212023-12-310000950170-24-034868EDGAR—
2023-03-222022-12-310000950170-23-009046EDGAR—
2022-03-292021-12-310000950170-22-004850EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-032025-09-300001193125-25-261696EDGAR55K words
2025-08-142025-06-300000950170-25-108906EDGAR—
2025-05-152025-03-310000950170-25-071996EDGAR—
2024-11-122024-09-300000950170-24-124602EDGAR—
2024-08-142024-06-300000950170-24-097073EDGAR—
2024-05-142024-03-310000950170-24-059099EDGAR—
2023-11-072023-09-300000950170-23-060354EDGAR—
2023-08-112023-06-300000950170-23-041605EDGAR—
2023-05-112023-03-310000950170-23-020836EDGAR—
2022-11-012022-09-300000950170-22-020701EDGAR—
2022-08-152022-06-300000950170-22-017222EDGAR—
2022-05-132022-03-310000950170-22-009807EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-230001193125-26-118525EDGAR4K words
2026-02-060001193125-26-041169EDGAR—
2025-12-180001193125-25-323704EDGAR—
2025-11-030001193125-25-261689EDGAR—
2025-08-140000950170-25-108898EDGAR—
2025-08-040000950170-25-101618EDGAR—
2025-07-030000950170-25-093456EDGAR—
2025-06-180000950170-25-087907EDGAR—
2025-05-150000950170-25-071992EDGAR—
2025-03-240000950170-25-043491EDGAR—

81 total filings indexed. 54 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001782223
TickerPYXS
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 2b285b86f417489992d38308c2d445885d5a894bbaa4b9c164364cc29c53cfad
parent: 0b22f5fa9cbece687c6bac07339e7eea70db15fd1dbb2dffa534e4de5d294ad2
content hash: 8c9f1804dbb72f89061785505e7369bf6476f1c701da70747d82e953a8c0ade5
signed: 2026-04-13T04:47:04.250Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf